Francesca Zacchi

Verona, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Interleukin-8: a tumor-agnostic biomarker integrating cancer biology and host response across solid tumors.

Interleukin-8: a tumor-agnostic biomarker integrating cancer biology and host response across solid tumors.

Journal: Cancer treatment reviews

Published: February 07, 2026

Multiparametric assessment of bone health in metastatic hormone-sensitive prostate cancer patients receiving androgen deprivation + enzalutamide ± zoledronic acid (BonEnza study).

Multiparametric assessment of bone health in metastatic hormone-sensitive prostate cancer patients receiving androgen deprivation + enzalutamide ± zoledronic acid (BonEnza study).

Journal: Bone

Published: January 12, 2026

Therapy-induced senescence in prostate cancer: mechanisms, therapeutic strategies, and clinical implications.

Therapy-induced senescence in prostate cancer: mechanisms, therapeutic strategies, and clinical implications.

Journal: Gene

Published: August 29, 2025

The role of therapeutic cancer vaccines in the modern immunotherapy era: State of the art with recent progress and future challenges.

The role of therapeutic cancer vaccines in the modern immunotherapy era: State of the art with recent progress and future challenges.

Journal: Critical reviews in oncology/hematology

Published: July 21, 2025

Interleukin-8 as a potential prognostic biomarker in renal cell carcinoma: a systematic review and meta-analysis.

Interleukin-8 as a potential prognostic biomarker in renal cell carcinoma: a systematic review and meta-analysis.

Journal: The oncologist

Published: April 05, 2025

Total and Regional Changes in Body Composition in Metastatic Hormone-sensitive Prostate Cancer Patients Randomized to Receive Androgen Deprivation + Enzalutamide ± Zoledronic Acid. The BONENZA Study.

Total and Regional Changes in Body Composition in Metastatic Hormone-sensitive Prostate Cancer Patients Randomized to Receive Androgen Deprivation + Enzalutamide ± Zoledronic Acid. The BONENZA Study.

Journal: European urology oncology

Published: December 16, 2024

Clinical outcomes of avelumab and pembrolizumab in advanced urothelial cancer: an observational multicenter retro-prospective study on patients undergoing treatment in clinical practice (AVePEm study).

Clinical outcomes of avelumab and pembrolizumab in advanced urothelial cancer: an observational multicenter retro-prospective study on patients undergoing treatment in clinical practice (AVePEm study).

Journal: Frontiers in oncology

Published: November 21, 2024

Addition of zoledronic acid to enzalutamide and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: the randomized phase II BONENZA trial.

Addition of zoledronic acid to enzalutamide and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: the randomized phase II BONENZA trial.

Journal: Prostate cancer and prostatic diseases

Published: November 17, 2024

Apalutamide in Metastatic Castration-sensitive Prostate Cancer: Results from the Multicenter Real-world ARON-3 Study.

Apalutamide in Metastatic Castration-sensitive Prostate Cancer: Results from the Multicenter Real-world ARON-3 Study.

Journal: European urology oncology

Published: October 02, 2024

Recent and Future Developments in the Use of Poly (ADP-ribose) Polymerase Inhibitors for Prostate Cancer.

Recent and Future Developments in the Use of Poly (ADP-ribose) Polymerase Inhibitors for Prostate Cancer.

Journal: European urology oncology

Published: October 01, 2024

Progresses and Pitfalls of Epigenetics in Solid Tumors Clinical Trials.

Progresses and Pitfalls of Epigenetics in Solid Tumors Clinical Trials.

Journal: International journal of molecular sciences

Published: August 31, 2024

Whole-body Diffusion-weighted Magnetic Resonance Imaging for Assessment of the Bone Response Rate in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Enzalutamide.

Whole-body Diffusion-weighted Magnetic Resonance Imaging for Assessment of the Bone Response Rate in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Enzalutamide.

Journal: European urology

Published: March 10, 2024

Showing 1-12 of 21

Last Updated: 09/26/2026